Rhythm Pharmaceuticals, Inc. (RYTM)

Market Cap	2.58B
Revenue (ttm)	91.93M
Net Income (ttm)	-273.87M
Shares Out	60.97M
EPS (ttm)	-4.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,203
Open	42.19
Previous Close	42.67
Day's Range	41.95 - 43.09
52-Week Range	15.50 - 52.57
Beta	1.93
Analysts	Strong Buy
Price Target	54.33 (+28.32%)
Earnings Date	Jul 30, 2024

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2017
• Employees: 226
• Stock Exchange: NASDAQ
• Ticker Symbol: RYTM

Financial Performance

In 2023, RYTM's revenue was $77.43 million, an increase of 227.56% compared to the previous year's $23.64 million. Losses were -$184.68 million, 1.97% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price forecast is $54.33, which is an increase of 28.32% from the latest price.

Price Target

$54.33

(28.32% upside)

Analyst Consensus: Strong Buy